Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group StudyMarcus E Randall, Virginia L Filiaci, Hyman Muss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2019
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid TumorsTanios Bekaii-Saab, Robert Wesolowski, Daniel H Ahn, et al.
Gynecologic Oncology|December 11, 2012
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, Robert A Burger, et al.
The International Journal of Artificial Organs|July 12, 2021
Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0Carly Fabrizio, Marissa N Levito, Ryan Rivosecchi, et al.
Gynecologic Oncology|July 29, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyJames S Ferriss, James J Java, Michael A Bookman, et al.
The American Journal of Cardiology|February 13, 2007
Analysis of interaction of acute atrial overdrive pacing with sleep-related breathing disorderAlaa A Shalaby, Charles W Atwood, Claudius Hansen, et al.
The New England Journal of Medicine|December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancerRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Investigative Radiology|August 8, 2009
Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancerWilliam T C Yuh, Nina A Mayr, David Jarjoura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
The International Journal of Artificial Organs|December 6, 2023
Cardiogenic shock etiology and exit strategy impact survival in patients with Impella 5.5McKenzie Sicke, Shan Modi, Yeahwa Hong, et al.
Pageof 4